Navigation Links
ARGX-110, a Novel Anti-CD70 Antibody, Meets Translational Development Goals in Dose Escalation Part of Phase Ib Cancer Study
Date:12/17/2013

BREDA, The Netherlands and GHENT, Belgium, December 17, 2013 /PRNewswire/ --

Dose confirmed for Phase Ib safety and efficacy expansion study

arGEN-X announces that the dose-escalation part of a Phase Ib study with its lead antibody ARGX-110 has met its translational development goals: all pre-specified biological activity measures (e.g. target engagement, effector functions, immune-modulation) were met. The study also showed that ARGX-110 has a favourable safety profile and a dose has been selected to advance into the Phase Ib safety and efficacy expansion cohorts, which will start early in 2014 and are expected to report top-line results approximately 12 months later.

ARGX-110 is a first-in-class monoclonal antibody potently blocking CD70 induced tumor proliferation and tumor escape from immune surveillance. In addition, the POTELLIGENT®-enhanced antibody-dependent cellular cytotoxicity (ADCC) of ARGX-110 enables selective destruction of CD70-positive tumor cells. CD70 is overexpressed in the majority of cancer patients tested to date. Expectations of a favourable therapeutic index stem from its virtual absence in healthy tissues.

In the study, 19 patients with CD70-positive cancer were treated with escalating doses of ARGX-110, up to 10 mg/kg. The results show predictable pharmacokinetics across the dose range. No dose-limiting toxicity was identified. For Ahmad Awada, MD PhD, principal investigator of the study at the Jules Bordet Institute (Brussels, Belgium), "these results, at the clinical and immunological levels, open the door to study further the antibody as a single agent and in combination trials with small molecules and other immune checkpoint inhibitors."

Based on these data, arGEN-X will begin enrolment to hematology and solid tumor safety and efficacy expansion cohorts early in 2014 and report top-line r
'/>"/>

SOURCE arGEN-X
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. The Market for Non-Small-Cell Lung Cancer (NSCLC) Will Grow to $7 Billion in 2022, Fuelled by the Entry of Twelve Novel Agents
2. The Acute Coronary Syndrome 12-Month Posthospital Market Will Double by 2022, Driven by the Uptake of Novel Lipid Modifying Agents
3. Sutro Biopharma Closes $26 Million Financing, Expands Development of Novel Immuno-Oncology Products
4. High Cost of Biologics and Novel Oral Agents to Treat Immune Diseases Limits Patient Access
5. Opportunity Exists in the U.S. for Novel Agents in Crohns Disease and Ulcerative Colitis, Owing to Discontinued Use of Leading Anti-TNF Agents Driven by Efficacy Failures
6. Synthetic Biologics Enters into License with Cedars-Sinai Medical Center to Develop Novel Anti-infective Approaches for Irritable Bowel Syndrome (IBS), Obesity and Diabetes
7. Bavarian Nordic, the international novel cancer and infectious disease vaccines focused biotech, now covered by Edison.
8. FLAG Therapeutics and Duquesne University Announce Exclusive Worldwide Licensing Agreement for Novel, Dual-action Targeted Oncology Compounds
9. Increasing Use of Allergans Botox and the Launch of Novel Nontriptan Products Will Be Key Drivers of Migraine Market Growth Through 2022
10. Novel Molecular Assay for Patient Screening Detects S. aureus and Newly Emerging MRSA Strains Available in the United States
11. Unilife Announces Clinical Supply Agreement for Delivery of a Novel Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... Research and Markets  has announced the ... Devices Market 2014-2018" report to their offering. ... cells that connect, support, or surround bones. There are ... ligaments, cartilage, fascia, and other fibrous tissues. Repetitive use, ... age result in wear and tear in these tissues. ...
(Date:8/28/2014)... 28, 2014 Reportlinker.com announces ... is available in its catalogue: ... Services Industry (U.S.): Analytics, Extensive Financial ... 2021, NAIC 541380 ... Testing Laboratories, Safety and Compliance Services ...
(Date:8/28/2014)... -- Pharmatech initiated enrollment for its AccessPPM program ... for matching cancer patients to cancer clinical trials. ... cancers, disease staging, and genetic mutations - which ... the first place. The challenge that the industry ... well known to the patient or even their ...
Breaking Medicine Technology:Global Orthopedic Soft Tissue Repair Devices Market 2014-2018: Key Vendors are ArthroCare, Biomet, DePuy Synthes and Smith & Nephew 2Global Orthopedic Soft Tissue Repair Devices Market 2014-2018: Key Vendors are ArthroCare, Biomet, DePuy Synthes and Smith & Nephew 3Testing Laboratories, Safety and Compliance Services Industry (U.S.): Analytics, Extensive Financial Benchmarks, Metrics and Revenue Forecasts to 2021, NAIC 541380 2Testing Laboratories, Safety and Compliance Services Industry (U.S.): Analytics, Extensive Financial Benchmarks, Metrics and Revenue Forecasts to 2021, NAIC 541380 3Testing Laboratories, Safety and Compliance Services Industry (U.S.): Analytics, Extensive Financial Benchmarks, Metrics and Revenue Forecasts to 2021, NAIC 541380 4Testing Laboratories, Safety and Compliance Services Industry (U.S.): Analytics, Extensive Financial Benchmarks, Metrics and Revenue Forecasts to 2021, NAIC 541380 5Testing Laboratories, Safety and Compliance Services Industry (U.S.): Analytics, Extensive Financial Benchmarks, Metrics and Revenue Forecasts to 2021, NAIC 541380 6Enrollment in Pharmatech's Revolutionary AccessPPM Program Launches 2
(Date:8/29/2014)... 29, 2014, 2 PM US Eastern Time)The current ... inject antibodies, commonly produced in animals, to neutralize ... from safety to difficulties in developing, producing and ... New research led by Charles Shoemaker, Ph.D., professor ... Health at the Cummings School of Veterinary Medicine ...
(Date:8/29/2014)... The microbiology testing sector is one of the ... is also the hugest challenge facing suppliers during these ... of AIDS – still the world’s key health threat ... opportunistic infections (OIs); bioterrorism threat; advancements in technologies for ... Although for certain infections the etiology remains a mystery, ...
(Date:8/29/2014)... FRIDAY, Aug. 29, 2014 (HealthDay News) -- Prostate cancer ... good treatment decisions. This can lead to worse quality ... The study included 70 men, with a median age ... cancer. Poor understanding of the disease was associated ... less confidence that the treatment would be effective, the ...
(Date:8/29/2014)... 2014 Edvance360, a leading provider of ... online teaching, as well as 2011 winner and six-time-finalist ... Management System, announced that Brooke Education Services, Northwest Academy, ... Interactive Advertising Bureau of Canada (IAB Canada), StarSVCS, and ... are delighted to welcome each new client to the ...
(Date:8/29/2014)... is a U.S. Food and Drug Administration (FDA)-approved ... raloxifene is as effective at reducing fracture risk ... by suppressing bone loss. With the use of ... respectively), researchers carried out experiments at the U.S. ... at Argonne National Laboratory that revealed an additional ...
Breaking Medicine News(10 mins):Health News:Mice study shows efficacy of new gene therapy approach for toxin exposures 2Health News:Infectious Disease Testing Universe Examined in New VPG Research Report Available at MarketPublishers.com 2Health News:Infectious Disease Testing Universe Examined in New VPG Research Report Available at MarketPublishers.com 3Health News:Faced With Prostate Cancer, It Helps to Know the Enemy 2Health News:Edvance360 Continues to Experience Growth in Corporate, K-12, Health, and Non-Profit Sectors 2Health News:Revealing a novel mode of action for an osteoporosis drug 2
... ... Roberto Giraldo shows that AIDS is a result of multiple, repeated and chronic exposure to ... and most of all, emotional. , ... Oakland, CA (PRWEB) November 8, 2009 -- From Nov. 6 – 8, 2009, ...
... Nov. 7 Today, the House of Representatives passed ... amendment to the "Affordable Health Care for America Act" ... preventing federal funding for abortion and for benefits packages ... who receive affordability credits and those who do not, ...
... H.R. 3961 to Secure the Stability of Medicare , ... M.D., President, American Medical Association. , (Logo: http://www.newscom.com/cgi-bin/prnh/20081209/AMALOGO ... the House health reform bill, which will help improve the ... passage of H.R. 3961 to secure the stability of the ...
... Calif., Nov. 8 March of Dimes hosted the ... individuals who are celebrating the birth of their children ... commitment to improve the health of babies. As ... Month campaign, celebrities and special guests were urged to ...
... , Jacquelyn T. Coleman (CT), David A. Cook ... David L. Tarver (LA) Honored , CHICAGO, Nov. ... five medical society executive leaders with achievement awards to ... the medical profession. The awards were presented at the ...
... , WASHINGTON, Nov. 7 The U.S. bishops November ... vote for the Stupak-Ellsworth Amendment to the health care ... current federal law on abortion funding and conscience protections ... 3962)," they said. , The letter was signed by ...
Cached Medicine News:Health News:Revolutionary New Views on AIDS Highlight the Rethinking AIDS 2009 Congress; Emotional Issues can be a Significant Contributing Factor 2Health News:Revolutionary New Views on AIDS Highlight the Rethinking AIDS 2009 Congress; Emotional Issues can be a Significant Contributing Factor 3Health News:Family Research Council Praises Passage of Pro-life Amendment to Health Care Bill 2Health News:AMA Hails House Passage of Health Reform Bill (H.R. 3962) 2Health News:Hollywood Stars Joined in a Celebration of Babies 2Health News:Hollywood Stars Joined in a Celebration of Babies 3Health News:AMA Honors Medical Society Executives 2Health News:Bishops Urge Passage of Stupak-Ellsworth Anti-Abortion Amendment for Health Reform Bill 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: